Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Down 74.5% in November

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 429,000 shares, a drop of 74.5% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 2,950,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.0% of the shares of the stock are sold short.

Cardio Diagnostics Stock Down 3.2 %

Shares of NASDAQ:CDIO traded down $0.01 during mid-day trading on Wednesday, hitting $0.30. The stock had a trading volume of 1,375,391 shares, compared to its average volume of 1,319,485. Cardio Diagnostics has a 12-month low of $0.19 and a 12-month high of $3.56. The company’s 50 day moving average is $0.26 and its 200-day moving average is $0.43.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “speculative buy” rating and set a $2.00 price objective on shares of Cardio Diagnostics in a research note on Tuesday, August 27th.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.